CryoCell International Company Leadership
| CCEL Stock | USD 8.57 0.28 3.38% |
CryoCell International employs about 82 people. The company is managed by 10 executives with a total tenure of roughly 112 years, averaging almost 11.0 years of service per executive, having 8.2 employees per reported executive. Inspection of CryoCell International's management performance can provide insight into the company performance.
| Mark Portnoy CEO Co-CEO and Director |
| David Portnoy Chairman Chairman and Co-CEO |
CryoCell |
CryoCell International's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with CryoCell International's future performance. Based on our forecasts, it is anticipated that CryoCell will maintain a workforce of about 80 employees by June 2024.CryoCell International Management Team Effectiveness
Return On Equity is expected to rise to 1.04 this year, although the value of Return On Tangible Assets are projected to rise to (0.14). At this time, CryoCell International's Other Assets are quite stable compared to the past year. Debt To Assets is expected to rise to 0.17 this year, although the value of Net Tangible Assets will most likely fall to (17.6 M). CryoCell International's management efficiency ratios could be used to measure how well CryoCell International manages its routine affairs as well as how well it operates its assets and liabilities.Common Stock Shares Outstanding is expected to rise to about 7.8 M this year, although the value of Net Income Applicable To Common Shares will most likely fall to about 2.1 M.
CryoCell International Workforce Comparison
CryoCell International is rated fourth in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 248,229. CryoCell International adds roughly 82.0 in number of employees claiming only tiny portion of equities under Health Care industry.
CryoCell International Profit Margins
The company has Profit Margin (PM) of (0.31) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.1 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.1.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.56 | 0.66 |
|
|
CryoCell International Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CryoCell International insiders, such as employees or executives, is commonly permitted as long as it does not rely on CryoCell International's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, CryoCell International insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2022-12-01 | 1.0833 | 13 | 12 | 130,691 | 65,974 |
| 2022-09-01 | 3.0 | 3 | 1 | 149,729 | 7,500 |
| 2021-12-01 | 2.6 | 13 | 5 | 890,600 | 434,447 |
| 2021-09-01 | 0.5789 | 11 | 19 | 183,990 | 250,761 |
| 2021-06-01 | 5.75 | 23 | 4 | 486,578 | 464,368 |
| 2021-03-01 | 3.5 | 14 | 4 | 33,581 | 4,471 |
| 2020-09-01 | 6.0 | 48 | 8 | 119,627 | 40,673 |
| 2020-06-01 | 1.6667 | 30 | 18 | 57,515 | 13,417,706 |
| 2019-12-01 | 0.9375 | 15 | 16 | 150,194 | 1,836,071 |
| 2019-09-01 | 10.0 | 10 | 1 | 161,652 | 20,000 |
| 2018-09-01 | 3.4 | 17 | 5 | 97,126 | 5,060,000 |
| 2018-03-01 | 1.1667 | 7 | 6 | 1,418,057 | 21,149 |
| 2017-06-01 | 0.3333 | 1 | 3 | 6,000 | 181,780 |
| 2017-03-01 | 6.0 | 6 | 1 | 410,543 | 9,281 |
| 2016-09-01 | 4.0 | 4 | 1 | 41,063 | 18,563 |
| 2015-09-01 | 1.5 | 6 | 4 | 58,100 | 70,000 |
| 2014-03-01 | 1.2 | 18 | 15 | 188,113 | 48,317 |
| 2012-09-01 | 16.0 | 16 | 1 | 44,603 | 7,500 |
| 2012-06-01 | 0.75 | 3 | 4 | 33,562 | 66,499 |
| 2011-12-01 | 1.5 | 6 | 4 | 442,500 | 42,500 |
| 2011-09-01 | 1.0 | 8 | 8 | 288,000 | 16,000 |
| 2009-09-01 | 4.0 | 8 | 2 | 136,251 | 7,708 |
| 2008-09-01 | 0.875 | 7 | 8 | 522,500 | 882,314 |
| 2007-09-01 | 4.5 | 9 | 2 | 430,030 | 0.00 |
| 2007-06-01 | 0.6667 | 2 | 3 | 40,000 | 36,424 |
| 2004-12-01 | 2.0 | 2 | 1 | 40,000 | 1,000.00 |
| 2004-09-01 | 0.1667 | 1 | 6 | 5,000 | 11,000 |
| 2003-09-01 | 6.0 | 6 | 1 | 580,000 | 50,000 |
CryoCell International Notable Stakeholders
A CryoCell International stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CryoCell International often face trade-offs trying to please all of them. CryoCell International's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CryoCell International's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Mark Portnoy | Co-CEO and Director | Profile | |
| David Portnoy | Chairman and Co-CEO | Profile | |
| Jill Taymans | CFO and VP of Fin. | Profile | |
| Arthur Ellis | Director | Profile | |
| Brian Sheehy | Director | Profile | |
| George Gaines | Director | Profile | |
| Jonathan Wheeler | Director | Profile | |
| Harold Berger | Director | Profile | |
| Joanne MD | Medical Board | Profile | |
| Oleg Mikulinsky | Chief Officer | Profile |
About CryoCell International Management Performance
The success or failure of an entity such as CryoCell International often depends on how effective the management is. CryoCell International management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CryoCell management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CryoCell management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.15) | (0.14) | |
| Return On Capital Employed | (0.27) | (0.26) | |
| Return On Assets | (0.14) | (0.15) | |
| Return On Equity | 0.99 | 1.04 |
The data published in CryoCell International's official financial statements usually reflect CryoCell International's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of CryoCell International. For example, before you start analyzing numbers published by CryoCell accountants, it's critical to develop an understanding of what CryoCell International's liquidity, profitability, and earnings quality are in the context of the Health Care Providers & Services space in which it operates.
Please note, the presentation of CryoCell International's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CryoCell International's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in CryoCell International's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CryoCell International. Please utilize our Beneish M Score to check the likelihood of CryoCell International's management manipulating its earnings.
CryoCell International Workforce Analysis
Traditionally, organizations such as CryoCell International use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CryoCell International within its industry.CryoCell International Manpower Efficiency
Return on CryoCell International Manpower
| Revenue Per Employee | 382.2K | |
| Revenue Per Executive | 3.1M | |
| Net Loss Per Employee | 116.1K | |
| Net Loss Per Executive | 952.2K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CryoCell International. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.Note that the CryoCell International information on this page should be used as a complementary analysis to other CryoCell International's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for CryoCell Stock analysis
When running CryoCell International's price analysis, check to measure CryoCell International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CryoCell International is operating at the current time. Most of CryoCell International's value examination focuses on studying past and present price action to predict the probability of CryoCell International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CryoCell International's price. Additionally, you may evaluate how the addition of CryoCell International to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is CryoCell International's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.25) | Earnings Share (1.16) | Revenue Per Share 3.783 | Quarterly Revenue Growth 0.004 | Return On Assets (0.01) |
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.